Genomic, proteomic and lipidomic evaluation of endometrial receptivity

Endometrial receptivity is a complex phenomenon that plays a vital role in infertility. Although quality of embryo can be evaluated for a successful implantation, endometrial receptivity is still an unknown factor. With advances in technology, the microarray approach has provided an ‘omic’ tool to evaluate endometrial receptivity. In Latin, ‘omic’ means the whole family. The genomic, proteomic, and lipidomic evaluations of endometrium mean a wholesome evaluation of the genes, lipids and proteins of the endometrium. Evaluation of receptivity with this three-way approach may provide insight to the potential markers of implantation. Genomic analysis has been limited to date because not every gene alteration affects protein expression. Lipidomic analysis has recently gained popularity because lipids are strictly controlled during the implantation period. In summary, with the recent advances in microarray technology, genomic, lipidomic, and proteomic analyses of the endometrium may provide ‘optimal’ evaluation tools and criteria to assess receptivity in the near future

Genomic, proteomic and lipidomic evaluation of endometrial receptivity

Endometrial receptivity is a complex phenomenon that plays a vital role in infertility. Although quality of embryo can be evaluated for a successful implantation, endometrial receptivity is still an unknown factor. With advances in technology, the microarray approach has provided an ‘omic’ tool to evaluate endometrial receptivity. In Latin, ‘omic’ means the whole family. The genomic, proteomic, and lipidomic evaluations of endometrium mean a wholesome evaluation of the genes, lipids and proteins of the endometrium. Evaluation of receptivity with this three-way approach may provide insight to the potential markers of implantation. Genomic analysis has been limited to date because not every gene alteration affects protein expression. Lipidomic analysis has recently gained popularity because lipids are strictly controlled during the implantation period. In summary, with the recent advances in microarray technology, genomic, lipidomic, and proteomic analyses of the endometrium may provide ‘optimal’ evaluation tools and criteria to assess receptivity in the near future

Torsion of a Pedunculated Subserous Leiomyoma in a Pregnant Woman: A Rare Case Report

Torsion of a pedunculated subserous leiomyoma in a pregnant woman is a rare condition that requires prompt diagnosis and urgent surgical intervention. In this report, we present a case of torsion of a pedunculated subserous leiomyoma in a primigravid woman aged 33 years in her 30th week of gestation. A primigravid woman aged 33 years presented to our clinic in her 30th week of gestation with pain in the right lower quadrant that had developed in the last 24 hours. Our diagnosis was torsion of a pedunculated leiomyoma. The patient received a tocolytic of nifedipine and indomethacin preoperatively. Given the volume of the uterus and as a precaution to potential complications, a lower transverse (pfannenstiel) incision was preferred. The laparotomic myomectomy was successfully performed and the pregnancy continued uneventfully. Even though torsion of a pedunculated subserous leiomyoma in pregnancy is a very rare condition, prompt diagnosis and urgent surgical intervention is life saving and provides more favorable maternal and fetal outcomes. The surgical approach should be tailored to the patient and to the characteristics of the myoma and an expert team of surgeons and anesthesiologists is essential in order to reduce the risk of complications

Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome

This prospective study aimed to determine the status of circulating levels of C-reactive protein (CRP), tumor necrosis factor alpha (TNF-alpha), IL-27, IL-35, IL-37, alpha-1 acid glycoprotein in patients with polycystic ovary syndrome (PCOS) compared with controls and to evaluate their relation with hyperandrogenism and obesity. Forty-eight patients with PCOS (29 obese, 19 lean) and 40 healthy controls (20 obese, 20 lean) were enrolled. CRP, TNF-alpha, IL-27, IL-35, IL-37, alpha-1 acid glycoprotein, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-S) levels were measured. Levels of total testosterone, A4, DHEA-S were significantly higher in patients with PCOS than in controls both in the obese and lean groups, while levels of SHBG were significantly lower in all patients with PCOS than in all (p < 0.05). Free androgen index (FAI) values were significantly higher in all patients with PCOS than in all controls (all p < 0.05). Levels of CRP, TNF-alpha, alpha-1 acid glycoprotein were significantly increased in all patients with PCOS compared with all controls (all p < 0.001). FAI had a positive correlation with CRP, TNF-alpha, alpha-1 acid glycoprotein, a negative correlation with IL-27, IL-25, IL-37 (all p50.01). Body mass index had a negative correlation with IL-27, IL-35, IL-37, a positive correlation with alpha-1 acid glycoprotein, FAI (p < 0.05). The findings confirm the proinflammatory state of PCOS. Moreover, obesity along with PCOS significantly elevates the inflammatory status and hyperandrogenism

A rational design of multi-functional nanoplatform: Fluorescent-based “off-on” theranostic gold nanoparticles modified with D-α-Tocopherol succinate

It is crucial to develop nanocarrier systems to detect and treat drug-resistant micro tumors to prevent recurrence and/or metastasis of cancer. Due to their exceptional features such as biocompatibility, easy surface modification, serving as imaging and therapeutic agent, gold nanoparticles (AuNPs) draw attention as theranostic agents. It is beneficial to combine AuNPs with a second imaging and/or treatment modality such as photodynamic therapy (PDT). PDT is a non-mutagenic treatment approach in which photosensitizer is activated with light, generating reactive oxygen species and/or free radicals to destroy tumor cells. With the aim of developing “off-on” theranostic system, citrate stabilized spherical 13 nm AuNPs were densely coated with polyethylene glycol (PEG). To advance the theranostic feature of PEGylated AuNPs, they were further functionalized with FDA-Approved photosensitizer, Verteporfin (BPD-MA). Due to static quenching between BPD-MA and AuNPs as well as in between nearby BPD-MA molecules, the fluorescence of the ground state complex is quenched and the system is in “off” state. When BPD-MA molecules are cleaved from the AuNPs surface and diffuse away, fluorescence is recovered. Consequently, the system switches to the “on” state. Among the various mole ratios of BPD-MA carrying conjugates prepared, the most promising candidate was selected based on stability, quenching factor, and fluorescence recovery rate. The conjugate was further decorated with D-α-Tocopherol succinate (VitES) to increase the therapeutic efficacy of the theranostic agent via enhancing cellular uptake. Our results showed that it was possible to achieve as high as 80 times fluorescence quenching when the system was “off”. As the system switched from “off” to “on” state, 51% of the fluorescence was recovered. When BPD-MA was immobilized on the PEGylated AuNPs, the phototoxic effect of BPD-MA increased twice against the MCF-7 cell line. Moreover, the developed system showed four times more phototoxicity than BPD-MA alone after it was decorated with VitES. Since the developed system is capable of dual imaging (computed tomography and fluorescence) and dual treatment (PDT and hyperthermia), it potentially offers superior imaging and therapy options for various types of in vitro/in vivo applications